Hearing loss and cognitive decline: Study probes link

CATHARINE PADDOCK PHD | January 30, 2019

article image
Recent research adds to a growing body of knowledge that links hearing loss with cognitive decline, which is a hallmark of dementia and often precedes the disease. After analyzing 8 years of data from a health study of more than 10,000 men, scientists at Brigham and Women's Hospital and Harvard Medical School, both in Boston, MA, found that hearing loss is tied to an appreciably higher risk of subjective cognitive decline.

Spotlight

Creativ-Ceutical

Creativ-Ceutical provides strategic pricing, market access and health economics consulting in life sciences. We provide both the strategic advice and the technical services to deliver results that meet your expectations. We have broad experience in the areas of central nervous system (CNS), oncology, vaccines, metabolic/cardiovascular diseases, and rare diseases. These are complex and developing fields, where treatment paradigms are in constant evolution and where clinical and economic issues require rigorous analysis to determine the best therapeutic choices. This experience allows us to address the most complex challenges and to anticipate pricing and market access issues that will arise in other therapeutic domains.

OTHER ARTICLES

3 Big Pharma Stocks Plunging the Most During the Coronavirus Stock Market Crash: Are They Buys?

Article | March 26, 2020

Big pharma stocks have been clobbered during the coronavirus-caused stock market crash. You can count the number of drugmakers with market caps of $25 billion or more whose shares haven't dropped by double-digit percentages on one hand -- and have several fingers left over. Three big pharma stocks have plunged the most: AbbVie (NYSE:ABBV), Bristol Myers Squibb (NYSE:BMY), and Pfizer (NYSE:PFE). But are these stocks smart picks to buy right now?

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | March 26, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | March 26, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

5 Pharma Trends and Their Impact on Packaging

Article | March 26, 2020

The pharmaceutical industry is changing at an unprecedented pace. New biological treatments for cancer, and a dramatic rise of widespread diseases such as diabetes, call for new processing and packaging solutions to fulfill the different needs all over the world. Keep your eye on these five main packaging trends for 2020 for the global pharmaceutical market.

Read More

Spotlight

Creativ-Ceutical

Creativ-Ceutical provides strategic pricing, market access and health economics consulting in life sciences. We provide both the strategic advice and the technical services to deliver results that meet your expectations. We have broad experience in the areas of central nervous system (CNS), oncology, vaccines, metabolic/cardiovascular diseases, and rare diseases. These are complex and developing fields, where treatment paradigms are in constant evolution and where clinical and economic issues require rigorous analysis to determine the best therapeutic choices. This experience allows us to address the most complex challenges and to anticipate pricing and market access issues that will arise in other therapeutic domains.

Events